22UA:FRA
BioNTech SE - ADR
€84.40
arrow_upward
+0.48%(+0.40) 1D
Sep 10, 10:13:20 AM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€83.95
High
€84.40
Low
€83.95
Mkt. cap
24.65B
Avg. vol.
1.13K
Volume
290.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
Open
€83.95
High
€84.40
Low
€83.95
Mkt. cap
24.65B
Avg. vol.
1.13K
Volume
290.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
News stories
From web sources and news partners
ad-hoc-news.de
·
10 hours ago
BioNTech's Insider Trades and Pipeline Bet: Two Signals, One Stock
Stock Titan
·
13 hours ago
BioNTech (BNTX) CEO sells part of his stake under preset trading plan
ad-hoc-news.de
·
18 hours ago
BioNTech's Seoul Moment: Can Two Antibodies Carry a Story That COVID Revenue No Longer Supports?
Kalkine Media
·
1 day ago
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR